ERBB2 oncogene

Vona, G., Caldini, A., Sestini, R., Rapi, S., Bianchi, S., Fanelli, A., Pazzagli, M., and Orlando, C. 1999. The c-erbB2 oncogene amplification by competitive PCR in aneuploid cell clones stored from breast cancer samples. Clin. Chem. Lab. Med. 37 649-654. 

Ulfelder KJ, Schwartz HE, Hall JM, Sunzeri FJ (1992) Restriction fragment length polymorphism analysis of ERBB2 oncogene by capillary electrophoresis. Anal Bio-chem 200 260-267. 

Xie, W., Chow, L. T., Paterson, A. J., Chin, E., and Kudlow, J. E. (1999) Conditional expression of the ErbB2 oncogene elicits reversible hyperplasia in stratified ep-ithelia and up-regulation of TGFalpha expression in transgenic mice. Oncogene 18, 3593-3607. 

Matsuda, S., Kadowaski, Y., Ichino, M., Akiyama, T., Toyoshima, K., and Yamamoto, T. 1993. 17/3-Estradiol mimics ligand activity of c-erbB2 proto-oncogene product. Proc. Natl. Acad. Sci. USA 90 10803-10807. 

Meden, H., Marx, D., Roegglen, T., Schauer, A., and Kuhn, W. 1998. Overexpression of the oncogene c-erbB2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer. Int. J. Gynecol. Pathol. 77 61-65. 

Holbro T, Beerli RR, Maurer F, et al. The ErbB2/ErbB3 heterodimer functions as an oncogenic unit ErbB2 requires ErbB3 to drive breast tumor cell proliferation. Proc Nail Acad Sci USA 2003, 100, 8933-8938. 

Harari, D., and Y. Yarden. 2000. Molecular mechanisms underlying ErbB2/HER2 action in breast cancer. Oncogene 19 6102-6114. 

---